Thalamostriatal degeneration contributes to dystonia and cholinergic interneuron dysfunction in a mouse model of Huntington's disease

被引:13
|
作者
Crevier-Sorbo, Gabriel [1 ]
Rymar, Vladimir V. [1 ]
Crevier-Sorbo, Raphael [1 ]
Sadikot, Abbas F. [1 ]
机构
[1] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada
基金
加拿大健康研究院; 加拿大自然科学与工程研究理事会;
关键词
Parafascicular; Striatum; Thalamus; R6; 2; Basal ganglia; Immunotoxin; NEUROCHEMICALLY IDENTIFIED PROJECTION; PARVALBUMIN-IMMUNOREACTIVE NEURONS; STRIATAL DOPAMINE RELEASE; NEUROTROPHIC FACTOR BDNF; SUBUNIT MESSENGER-RNAS; MUTANT HUNTINGTIN; GABAERGIC INTERNEURONS; BASAL GANGLIA; CELL LOSS; RETROGRADE TRANSPORT;
D O I
10.1186/s40478-020-0878-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease (HD) is an autosomal dominant trinucleotide repeat disorder characterized by choreiform movements, dystonia and striatal neuronal loss. Amongst multiple cellular processes, abnormal neurotransmitter signalling and decreased trophic support from glutamatergic cortical afferents are major mechanisms underlying striatal degeneration. Recent work suggests that the thalamostriatal (TS) system, another major source of glutamatergic input, is abnormal in HD although its phenotypical significance is unknown. We hypothesized that TS dysfunction plays an important role in generating motor symptoms and contributes to degeneration of striatal neuronal subtypes. Our results using the R6/2 mouse model of HD indicate that neurons of the parafascicular nucleus (PF), the main source of TS afferents, degenerate at an early stage. PF lesions performed prior to motor dysfunction or striatal degeneration result in an accelerated dystonic phenotype and are associated with premature loss of cholinergic interneurons. The progressive loss of striatal medium spiny neurons and parvalbumin-positive interneurons observed in R6/2 mice is unaltered by PF lesions. Early striatal cholinergic ablation using a mitochondrial immunotoxin provides evidence for increased cholinergic vulnerability to cellular energy failure in R6/2 mice, and worsens the dystonic phenotype. The TS system therefore contributes to trophic support of striatal interneuron subtypes in the presence of neurodegenerative stress, and TS deafferentation may be a novel cell non-autonomous mechanism contributing to the pathogenesis of HD. Furthermore, behavioural experiments demonstrate that the TS system and striatal cholinergic interneurons are key motor-network structures involved in the pathogenesis of dystonia. This work suggests that treatments aimed at rescuing the TS system may preserve important elements of striatal structure and function and provide symptomatic relief in HD.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Chen, Xi
    Wu, Jun
    Lvovskaya, Svetlana
    Herndon, Emily
    Supnet, Charlene
    Bezprozvanny, Ilya
    MOLECULAR NEURODEGENERATION, 2011, 6
  • [42] Brain pericyte response in a mouse model of Huntington's disease
    Padel, T.
    Ozen, I.
    Roth, M.
    Paul, G.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 479 - 479
  • [43] Progressive neuronal atrophy in a mouse model of Huntington's disease
    Raza, A. S.
    Davies, S. W.
    JOURNAL OF ANATOMY, 2007, 210 (05) : 607 - 607
  • [44] Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease
    Mielcarek, Michal
    Inuabasi, Linda
    Bondulich, Marie K.
    Muller, Thomas
    Osborne, Georgina F.
    Franklin, Sophie A.
    Smith, Donna L.
    Neueder, Andreas
    Rosinski, Jim
    Rattray, Ivan
    Protti, Andrea
    Bates, Gillian P.
    PLOS GENETICS, 2014, 10 (08):
  • [45] Dystonia in Huntington's disease: Prevalence and clinical characteristics
    Louis, ED
    Lee, P
    Quinn, L
    Marder, K
    MOVEMENT DISORDERS, 1999, 14 (01) : 95 - 101
  • [46] Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms
    Giralt, Albert
    Saavedra, Ana
    Alberch, Jordi
    Perez-Navarro, Esther
    JOURNAL OF HUNTINGTONS DISEASE, 2012, 1 (02) : 155 - 173
  • [47] Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
    Turmaine, M
    Raza, A
    Mahal, A
    Mangiarini, L
    Bates, GP
    Davies, SW
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) : 8093 - 8097
  • [48] Studies of a knock-in mouse model of Huntington's disease
    Hickey, MA
    Thomasian, SE
    Gruen, E
    Zeitlin, S
    Li, XJ
    Faull, KF
    Levine, MS
    Chesselet, MF
    MOVEMENT DISORDERS, 2003, 18 (09) : 1091 - 1091
  • [49] Behavioural assessment of a mouse genetic model of Huntington's disease
    Johnston, HM
    Ennis, M
    Myers, RM
    Shelbourne, PF
    BRAIN RESEARCH, 1998, 809 (01) : A26 - A26
  • [50] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Xi Chen
    Jun Wu
    Svetlana Lvovskaya
    Emily Herndon
    Charlene Supnet
    Ilya Bezprozvanny
    Molecular Neurodegeneration, 6